Effects of olanzapine and paroxetine on phospholipase D activity in the rat brain

Pharmacological Reports

Volumn 65, Issue 3, 2013, Pages 724-729

  Krzystanek, Marek ^a   Krzystanek, Ewa ^a   Trzeciak, Henryk I ^a   Małecki, Andrzej ^a,b   Krupka Matuszczyk, Irena ^a   Janas Kozik, Małgorzata ^a   Rybakowski, Janusz K ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF SPORT SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antidepressants; Neuroleptics; Olanzapine; Paroxetine; Phospholipase D (PLD); Rats

Indexed keywords

OLANZAPINE; PAROXETINE; PHOSPHOLIPASE D; RITANSERIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL MEMBRANE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUOROMETRY; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL MEMBRANE; CEREBRAL CORTEX; MALE; PAROXETINE; PHOSPHOLIPASE D; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN UPTAKE INHIBITORS;

EID: 84884494396     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71051-x     Document Type: Article

References (34)

1. Aravagiri M, Teper Y, Marder R: Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos, 1999, 20, 369-377. (Pubitemid 30449775)
2. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR: Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol, 2008, 23, 574-591.
3. Bobeszko M, Czajkowski R, Wójcik M, Sabała P, Lei L, Nalepa I, Barańska J: Modulation by cationic amphiphilic drugs of serine base-exchange, phosholipase D and intracellular calcium homeostasis in glioma C6 cells. Pol J Pharmacol, 2002, 54, 483-493. (Pubitemid 35214974)
4. Bobo WV, Shelton RC: Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother, 2009, 10, 2145-2159.
5. Chalifa V, Mohn H, Liscovitch M: A neutral phospholipase D activity from rat brain synaptic plasma membranes. J Biol Chem, 1990, 265, 17512-17519.
6. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E: Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol, 2009, 29, 1-10.
7. H]paroxetine in the rat brain. Synapse, 1993, 15, 124-129. (Pubitemid 23311583)
8. 1 isozyme in rat brain. Neuropharmacology, 2002, 43, 1269-1279. (Pubitemid 36084437)
9. English D, Cui Y, Siddiqui RA: Messenger functions of phosphatidic acid. Chem Phys Lipids, 1996, 80, 117-132. (Pubitemid 26197040)
10. Exton JH: Regulation of phospholipase D. Biochim Biophys Acta, 1999, 1439, 121-133. (Pubitemid 29333126)
11. Jelsema CL: Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins. J Biol Chem, 1987, 262, 163-168.
12. Jin JK, Ahn BH, Na YJ, Kim JI, Kim YS, Choi EK, Ko YG et al.: Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease. Neurobiol Aging, 2007, 28, 1015-1027.
13. Klein J: Functions and pathophysiological roles of phospholipase D in the brain. J Neurochem, 2005, 94, 1473-1487. (Pubitemid 41324632)
14. Krzystanek M, Trzeciak HI, Krzystanek E, Małecki A: Fluorometric assay of oleate-activated phospholipase D isoenzyme in membranes of rat nervous tissue and human platelets. Acta Biochim Pol, 2010, 57, 369-372.
15. Kuroki T, Meltzer HY, Ichikawa J: Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther, 1999, 288, 774-781. (Pubitemid 29119694)
16. Liscovitch M, Czarny M, Fiucci G, Lavie Y, Tang X: Localization and possible functions of phospholipase D isozymes. Biochim Biophys Acta, 1999, 1439, 245-263. (Pubitemid 29333135)
17. Löffelholz K: Receptor regulation of choline phospholipid hydrolysis. A novel source of diacylglycerol and phosphatidic acid. Biochem Pharmacol, 1989, 38, 1543-1549. (Pubitemid 19120070)
18. Lotharius J, Brundin P: Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet, 2002, 11, 2395-2407. (Pubitemid 35174703)
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem, 1951, 193, 265-275.
20. Maj J, Bijak M, Dziedzicka-Wasylewska M, Rogoż R, Rogóż Z, Skuza G, Tokarski K: The effects of paroxetine given repeatedly on the 5-HT receptors subpopulations in the rat brain. Psychopharmacology, 1996, 127, 73-77.
21. Malhi GS, Adams D, Berk M: Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord, 2009, 11, Suppl 2, 55-76.
22. 18F]setoperone PET imaging study. Am J Psychiatry, 2001, 158, 78-85. (Pubitemid 32047250)
23. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E et al., STOP-PD Group: A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry, 2009, 66, 838-847.
24. Nemeroff CB: Recent advances in the neurobiology of depression. Psychopharmacol Bull, 2002, 36, 6-23.
25. Nishida A, Emoto K, Shimizu M, Uozumi T, Yamawaki S: Brain ischemia decreases phosphatidylcholine-phospholipase D but not phosphatidylinositol- phospholipase C in rats. Stroke, 1994, 25, 1247-1251. (Pubitemid 24164769)
26. Peroutka S, Snyder SH: Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science, 1980, 210, 88-90. (Pubitemid 11192054)
27. Preininger AM, Henage LG, Oldham WM, Yoon EJ, Hamm HE, Brown HA: Direct modulation of phospholipase D activity by Gβγ. Mol Pharmacol, 2006, 70, 311-318.
28. 2A receptor. Mol Pharmacol, 2003, 64, 1239-1250. (Pubitemid 37310756)
29. Selvy PE, Lavieri RR, Lindsley CW, Brown HA: Phospholipase D-enzymology, functionality, and chemical modulation. Chem Rev, 2011, 111, 6064-6119.
30. Strosznajder J, Strosznajder RP: Guanine nucleotides and fluoride enhance carbachol-mediated arachidonic acid release from phosphatidylinositol. Evidence for involvement of GTP-binding protein on phospholipase A2 activation. J Lipid Mediat, 1989, 1, 217-229. (Pubitemid 19214119)
31. Szumiło M, Rahden-Staroń I: Phospholipase D in mammalian cells: structure, properties, physiological and pathological role (Polish). Postepy Hig Med Dosw, 2006, 60, 421-430.
32. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL: Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord, 2009, 116, 43-50.
33. Varga A, Alling C: Formation of phosphatidylethanol in vitro in red blood cells from healthy volunteers and chronic alcoholics. J Lab Clin Med, 2002, 140, 79-83. (Pubitemid 35028781)
34. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP: A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem, 1997, 253, 162-168. (Pubitemid 27508167)